Oramed Pharmaceuticals' (ORMP) “Neutral” Rating Reiterated at HC Wainwright - Defense World
Genmab A/S's (GMAB) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Kiora Pharmaceuticals' (KPRX) “Buy” Rating Reiterated at HC Wainwright - Defense World
Canaan (NASDAQ:CAN) Receives Buy Rating from HC Wainwright - Defense World
BridgeBio Pharma (NASDAQ:BBIO) PT Lowered to $43.00 at HC Wainwright - Defense World
Desktop versie